Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a ...

Fintel reports that on February 24, 2025, Wells Fargo downgraded their outlook for Exelixis (NasdaqGS:EXEL) from Overweight ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36.Discover the Best Stocks and ...

Wells Fargo downgraded Exelixis (EXEL) to Equal Weight from Overweight with an unchanged price target of $36. While there is a better chance ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

To properly understand Exelixis' profit results, we need to consider the US$85m expense attributed to unusual items. While deductions due to unusual items are disappointing in the first instance ...

Operator Good day, ladies and gentlemen, and welcome to the Exelixis fourth quarter and fiscal year 2024 financial results ...

Exelixis reported $515.2M in net product revenues in Q4'24, a 20% increase over net product revenues for Q4'23. See why I ...